FDA Approves First New Sunscreen Chemical Filter in Nearly 30 Years: What Bemotrizinol Actually Does

Since we last covered the broader FDA regulatory landscape, the agency has moved on a consumer health front that has nothing to do with politics and everything to do with skin cancer: the approval of bemotrizinol, a chemical UV filter that has been standard in European and Asian sunscreens for roughly 20 years.

The FDA cleared bemotrizinol on June 13, 2026, according to NPR. It is the first new chemical UV filter approved for use in U.S. sunscreens in close to three decades.

What Bemotrizinol Actually Does Differently

Most sunscreens sold in the U.S. are technically "broad spectrum," meaning they claim to block both UVA and UVB rays. The problem, according to Dr. Heather Rogers, a Seattle dermatologist and fellow of the American Academy of Dermatology, is that the UVA protection in American sunscreens has been the weak link.

U.S. chemical sunscreens have relied heavily on a compound called avobenzone to handle UVA blocking. Cosmetic chemist Kelly Dobos, who teaches at the University of Cincinnati, told NPR that avobenzone is not photo stable on its own — meaning it starts breaking down relatively quickly under sunlight exposure. As it degrades, it can release molecules that irritate skin, according to Alexa Friedman, a senior scientist at the Environmental Working Group.

Bemotrizinol blocks both UVA and UVB rays independently, and it is photo stable — it holds up longer under sun exposure than avobenzone does. Rogers told NPR that this means a user who goes slightly past the two-hour reapplication window will have more residual protection than they would with current U.S. formulations. She described it as hitting "really every box for us that we have been waiting for as dermatologists and consumers."

Why Did This Take So Long?

The fair concern worth stating plainly: U.S. consumers have had access to inferior sunscreen chemistry compared to Europeans and Asians for decades, and the FDA's approval process for sunscreen ingredients is widely seen by dermatologists and cosmetic chemists as slow and burdensome. Bemotrizinol's long record of safe use abroad raises a legitimate question about whether American regulatory caution served public health here, given that UV exposure is the leading cause of skin cancer — the most diagnosed cancer in the United States.

That is a real and reasonable grievance. The FDA's sunscreen ingredient review process was restructured by Congress under the Modernization of Cosmetics Regulation Act of 2022, which was designed specifically to accelerate the kind of review that led to this approval. The bemotrizinol clearance may be an early sign that the process is actually moving.

No allegations of regulatory corruption or political interference surround this approval. It appears to be a straightforward scientific review that reached the finish line.

What It Means for Products on Shelves

Approval does not mean bemotrizinol-based sunscreens are available to buy today, June 13, 2026. Manufacturers will now need to formulate, test, and bring products to market. Rogers' enthusiasm suggests dermatologists will push for adoption quickly, but there is no announced timeline from any major sunscreen brand in these sources for when consumers will see it on shelves.

The ingredient's existing track record in Europe and Asia reduces the unknowns significantly. It is not an experimental compound — it has been applied to millions of people over two decades with a documented safety profile.

The Practical Takeaway for Right Now

Existing broad-spectrum sunscreens with SPF 30 or higher still provide meaningful protection against skin cancer. Rogers told NPR that current U.S. sunscreens do an excellent job on UVB rays; the UVA gap has been real but not zero. Skipping sunscreen entirely while waiting for bemotrizinol products would be the wrong move.

The unresolved question as of today is speed. How quickly will U.S. manufacturers reformulate or launch new products using bemotrizinol, and will the pricing reflect the ingredient's novelty or its already-commodity status in global markets where it has been in use for years? That will determine whether this FDA approval translates into a practical upgrade for American consumers or simply sits as a regulatory win on paper for the next several years.